Literature DB >> 11784151

Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.

Xiankai Sun1, Melinda Wuest, Gary R Weisman, Edward H Wong, David P Reed, C Andrew Boswell, Ramunas Motekaitis, Arthur E Martell, Michael J Welch, Carolyn J Anderson.   

Abstract

Macrocyclic chelators and their metal complexes have widespread applications in the biomedical sciences, including radiopharmaceutical chemistry. The use of copper radionuclides in radiopharmaceuticals is increasing. Macrocyclic chelators have been found to have enhanced in vivo stability over acyclic chelators such as ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). The currently used chelators of choice for labeling copper radionuclides to biological molecules are analogues of TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid); however, recent reports have demonstrated evidence of in vivo instability of the radio-Cu(II)-TETA complexes. A new class of structurally reinforced macrocycles, the "cross-bridged" cyclam derivatives, form highly stable complexes with Cu(II) that are resistant to dissociation in strong acid. Here, we evaluate a series of (64)Cu(II) cross-bridged macrocyclic complexes for biological stability and in vivo behavior. The ligands evaluated include the parent ligand, 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (1), and three 4,11-di-pendant arm derivatives: 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (2); 4,11-bis(N,N-diethyl-amidomethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (3); and 4,11-bis(amidoethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (4). Copper-64 formed complexes with ligands 1-4 in high radiochemical yields. The (64)Cu-2 complex was neutral, while (64)Cu complexes of 1, 3, and 4 were positively charged. All complexes showed no decomposition in rat serum out to 24 h. Biodistribution experiments in Sprague-Dawley rats indicated that (64)Cu-1, -3, and -4 were taken up by the liver and kidney and cleared slowly over 24 h, whereas (64)Cu-2 cleared rapidly from all tissues. The rapid clearance of the (64)Cu-2 complex from the blood and liver, as well as liver metabolism experiments in rats, suggests that it is highly stable in vivo. A bifunctional chelator of 2 is a significant candidate for labeling copper radionuclides to biological molecules for diagnostic imaging and targeted radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11784151     DOI: 10.1021/jm0103817

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  58 in total

1.  Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.

Authors:  Yunjun Guo; Riccardo Ferdani; Carolyn J Anderson
Journal:  Bioconjug Chem       Date:  2012-06-18       Impact factor: 4.774

2.  In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.

Authors:  Jeffrey M Craft; Ravindra A De Silva; Kimberly A Lears; Rebecca Andrews; Kexian Liang; Samuel Achilefu; Buck E Rogers
Journal:  Nucl Med Biol       Date:  2012-01-20       Impact factor: 2.408

3.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Authors:  Maggie S Cooper; Michelle T Ma; Kavitha Sunassee; Karen P Shaw; Jennifer D Williams; Rowena L Paul; Paul S Donnelly; Philip J Blower
Journal:  Bioconjug Chem       Date:  2012-04-13       Impact factor: 4.774

Review 4.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Authors:  Thaddeus J Wadas; Christopher D Sherman; Jeffrey H Miner; James R Duncan; Carolyn J Anderson
Journal:  Magn Reson Med       Date:  2010-11       Impact factor: 4.668

6.  Novel hexadentate and pentadentate chelators for ⁶⁴Cu-based targeted PET imaging.

Authors:  Inseok Sin; Chi Soo Kang; Nilantha Bandara; Xiang Sun; Yongliang Zhong; Buck E Rogers; Hyun-Soon Chong
Journal:  Bioorg Med Chem       Date:  2014-03-01       Impact factor: 3.641

7.  Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals.

Authors:  Shuanglong Liu; Zibo Li; Li-Peng Yap; Chiun-Wei Huang; Ryan Park; Peter S Conti
Journal:  Chemistry       Date:  2011-08-04       Impact factor: 5.236

8.  Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling.

Authors:  C Andrew Boswell; Celeste A S Regino; Kwamena E Baidoo; Karen J Wong; Ambika Bumb; Heng Xu; Diane E Milenic; James A Kelley; Christopher C Lai; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2008-07-03       Impact factor: 4.774

9.  Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature.

Authors:  Kai Chen; Xilin Sun; Gang Niu; Ying Ma; Li-Peng Yap; Xiaoli Hui; Kaichun Wu; Daiming Fan; Peter S Conti; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

10.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.